DF/HCC Program Affiliation

Member, Prostate Cancer Program
Member, Neuro-Oncology Program
Member, Cancer Immunology Program

DF/HCC Associations

Director, Vector Core
Member, Center Scientific Council

Research Abstract

Dr. Mulligan's laboratory is primarily interested in the development of methods for introducing genes into mammalian cells, and the application of those methods in a number of areas of cell biology, developmental biology, virology and medicines. The current research activities of his laboratory are focused in three general areas: (i) the control of hematopoiesis, (ii) manipulation of the immune response via gene transfer, and (iii) the development of new mammalian gene transfer vectors.

Publications

• Mostoslavsky G, Fabian AJ, Rooney S, Alt FW, Mulligan RC. Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A 2006 Oct 31; 103(44):16406-11
  PMID: 17062750
• Murphy GJ, Mostoslavsky G, Kotton DN, Mulligan RC. Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med 2006 Sep; 12(9):1093-9
  PMID: 16892063
• Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, Yuan J, Hefner C, Chartier C, Lee JS, Jiang S, Niyak NR, Kuypers FA, Ma L, Sundram U, Wu G, Garcia JA, Schrier SL, Maher JJ, Johnson RS, Yancopoulos GD, Mulligan RC, Kuo CJ. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006 Jul; 12(7):793-800
  PMID: 16799557
• Yen L, Magnier M, Weissleder R, Stockwell BR, Mulligan RC. Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA 2006 May; 12(5):797-806
  PMID: 16556935
• Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, Kiryu S, Kung AL, Mulligan RC, Carter BS. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006 Feb; 58(2):365-72; discussion 365-72
  PMID: 16462491
• Balazs AB, Fabian AJ, Esmon CT, Mulligan RC. Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. Blood 2006 Mar 15; 107(6):2317-21
  PMID: 16304059
• Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, Kunkel LM, Mulligan RC. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999 Sep 23; 401(6751):390-4
  PMID: 10517639
• Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, Johnson RP. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997 Dec; 3(12):1337-45
  PMID: 9396603
• Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996 Apr 1; 183(4):1797-806
  PMID: 8666936